Brukinsa Europska Unija - hrvatski - EMA (European Medicines Agency)

brukinsa

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastična sredstva - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Hemlibra Europska Unija - hrvatski - EMA (European Medicines Agency)

hemlibra

roche registration limited - emicizumab - hemofilija a - antihemorrhagics - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra mogu se koristiti u svim dobnim skupinama.

Tavneos Europska Unija - hrvatski - EMA (European Medicines Agency)

tavneos

vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - imunosupresivi - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).

Aspaveli Europska Unija - hrvatski - EMA (European Medicines Agency)

aspaveli

swedish orphan biovitrum ab (publ) - pegcetacoplan - hemoglobinuria, paroxysmal - imunosupresivi - aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh) who are anaemic after treatment with a c5 inhibitor for at least 3 months.

Leqvio Europska Unija - hrvatski - EMA (European Medicines Agency)

leqvio

novartis europharm limited - inclisiran - hypercholesterolemia; dyslipidemias - sredstva za modifikaciju lipida - leqvio is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach ldl-c goals with the maximum tolerated dose of a statin, oralone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.

GRIPPOSTAD COMPLEX 30 mg/1 kesica+ 500 mg/1 kesica granule za oralnu suspenziju Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

grippostad complex 30 mg/1 kesica+ 500 mg/1 kesica granule za oralnu suspenziju

hemofarm proizvodnja farmaceutskih proizvoda d.o.o. banja luka - acetil salicilna kiselina, pseudoefedrin - granule za oralnu suspenziju - 30 mg/1 kesica+ 500 mg/1 kesica - jedna kesica sadrži: 30 mg pseudoefedrinhidrohlorida i 500 mg acetilsalicilne kiseline.

Rekovelle Europska Unija - hrvatski - EMA (European Medicines Agency)

rekovelle

ferring pharmaceuticals a/s - follitropin delta - anovulacija - spolni hormoni i modulatori genitalnog sustava, - kontrolirana stimulacija jajnika za razvoj folikula u žena prolazi asistirane reproduktivne tehnologije (art) kao što je oplodnja (ivf) ili intracitoplazmična injekcija spermija (icsi) ciklus.